Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
2.
IDCases ; 31: e01654, 2023.
Article in English | MEDLINE | ID: mdl-36478666

ABSTRACT

We report a case of Talaromyces marneffei fungemia in a patient with HIV infection with a history of travelling to southern China. At first, Pneumocystis pneumonia was considered in this case because chest CT images showed typical ground-glass opacity and elevated ß-D-glucan levels. However, PCR testing of sputum for Pneumocystis jirovecii was negative and a filamentous fungus was isolated from blood cultures. The cultured fungus was subsequently identified as T. marneffei, and the patient was considered to have pneumonia caused by this organism. However, skin disease and lymphadenopathy, which are common in T. marneffei infections, were not observed during the disease course. This patient was successfully treated with voriconazole and consequently the chest CT shadow disappeared. In the present case, T. marneffei infection required differentiation from pneumonia with Pneumocystis jirovecii infection.

3.
Cancer Rep (Hoboken) ; 5(10): e1689, 2022 10.
Article in English | MEDLINE | ID: mdl-35899993

ABSTRACT

BACKGROUND: Mucosa associated lymphoid tissue (MALT) lymphoma of the orbit is rare, often indolent, but can recur, and spread to extra-nodal sites. Pleural and retroperitoneum recurrences of MALT lymphoma are rare. CASE: A 65-year-old man was referred to our hospital due to right pleural effusion and difficulty in breathing. He had a medical history of having undergone surgery for MALT lymphoma of the left orbit. A chest computed tomography (CT) scan showed right pleural thickness, pleural effusion, and a retroperitoneal mass, spreading from the muscular layer to the subcutaneous layer. The thickened pleural lesion was surgically biopsied and diagnosed as a recurrence of MALT lymphoma. CONCLUSION: Pleural effusion should be carefully examined and monitored for the possibility of recurrence in MALT lymphoma patients.


Subject(s)
Lymphoma, B-Cell, Marginal Zone , Pleural Effusion , Aged , Humans , Lymphoma, B-Cell, Marginal Zone/diagnostic imaging , Lymphoma, B-Cell, Marginal Zone/surgery , Male , Orbit/pathology , Pleura/diagnostic imaging , Pleura/pathology , Pleura/surgery , Pleural Effusion/pathology , Tomography, X-Ray Computed
4.
Thorac Cancer ; 13(10): 1479-1489, 2022 05.
Article in English | MEDLINE | ID: mdl-35394119

ABSTRACT

BACKGROUND: Biomarker assessments for nivolumab monotherapy efficacy in previously treated patients with non-small cell lung cancer (NSCLC) remain unclear. We evaluated whether body mass index (BMI) and Glasgow prognostic score (GPS) are useful for assessing the efficacy of nivolumab alone as a second-line treatment in patients with pretreated NSCLC. METHODS: Data of 99 patients treated with second-line nivolumab monotherapy for NSCLC between January 2016 and December 2019 were evaluated for prognostic values of BMI and GPS to assess their usefulness in predicting progression-free survival (PFS) and overall survival (OS). RESULTS: The Eastern Cooperative Oncology Group-performance status (PS) independently predicted the second-line nivolumab monotherapeutic effect; good PS (0-1) correlated with significantly longer PFS (4.3 vs. 1.9 months, log-rank; p = 0.0004) and OS (17.7 vs. 4.6 months, log-rank; p < 0.0001) than poor PS. BMI independently predicted survival, with high BMI (≥22.1 kg/m2 ) associated with significantly longer OS (19.1 vs. 8.5 months, log-rank; p = 0.0023) than low BMI (<22.1 kg/m2 ). However, GPS showed no significant difference for PFS or OS. CONCLUSION: Among patients with NSCLC treated with nivolumab monotherapy as second-line treatment, PS was significantly correlated with both PFS and OS and BMI with OS. Thus, BMI could be a useful predictor of survival in these patients.


Subject(s)
Carcinoma, Non-Small-Cell Lung , Lung Neoplasms , Body Mass Index , Carcinoma, Non-Small-Cell Lung/drug therapy , Humans , Lung Neoplasms/drug therapy , Nivolumab/pharmacology , Nivolumab/therapeutic use , Prognosis , Retrospective Studies
5.
J Infect Chemother ; 28(2): 304-307, 2022 Feb.
Article in English | MEDLINE | ID: mdl-34772624

ABSTRACT

A 67-year-old Japanese man was admitted to our hospital with severe coronavirus disease 2019 (COVID-19) in March 2020. Mechanical ventilation was initiated 8 days after admission, due to severe respiratory failure. Multiple severe complications such as liver dysfunction, arrhythmia, brain infarction, and venous thromboembolism were also observed. We initially diagnosed Coombs test-positive warm autoimmune hemolytic anemia. Corticosteroids proved ineffective and anemia worsened with severe erythroid hypoplasia (0.5% erythroblasts in bone marrow), so we diagnosed pure red cell aplasia (PRCA). We also identified massive infiltration of cytotoxic T-lymphocytes expressing CD8, granzyme B, and perforin in bone marrow. Systemic cyclosporine was started, with full resolution of anemia and no need for blood transfusions after 4 weeks. We believe that this represents the first report of COVID-19-associated PRCA successfully treated using cyclosporine.


Subject(s)
Anemia, Hemolytic, Autoimmune , COVID-19 , Red-Cell Aplasia, Pure , Aged , Anemia, Hemolytic, Autoimmune/drug therapy , Cyclosporine/therapeutic use , Humans , Male , Red-Cell Aplasia, Pure/drug therapy , SARS-CoV-2
6.
Asia Pac Allergy ; 11(3): e32, 2021 Jul.
Article in English | MEDLINE | ID: mdl-34386408

ABSTRACT

BACKGROUND: Allergen immunotherapy (AIT) is a specific treatment of administering clinically important allergens to patients who have allergic diseases. In Japan, the standardized house dust mite (HDM) allergen for subcutaneous immunotherapy (SCIT) was approved in 2015, and we then introduced rush-immunotherapy (rush-IT) using the standardized HDM allergen for HDM-sensitive asthmatics. However, little data are available on the safety and effectiveness of rush-HDM-IT, especially for Japanese asthmatics. OBJECTIVE: The objective of this study was to examine the safety and clinical effectiveness of rush-IT using the standardized HDM for HDM-sensitive Japanese asthmatics. METHODS: Thirteen HDM-sensitive asthmatics who received rush-HDM-IT and 12 HDM-sensitive asthmatic controls were enrolled. To evaluate the safety, the number of systemic reaction (SR) events, including anaphylaxis, was assessed. To evaluate the effectiveness, changes in the treatment step, dose of inhaled corticosteroid, and asthma control after rush-HDM-IT and the subsequent maintenance SCIT were assessed. Changes in the HDM-induced production of type 2 cytokines from peripheral blood mononuclear cells were also evaluated. RESULTS: Among the 12 patients who received rush-IT, 4 (30.7%) experienced a SR and 3 (23.1%) experienced anaphylaxis. However, the anaphylaxis was not severe (grade 3) in all cases, and they recovered in a short time. The treatment step of asthma was better and the dose of inhaled corticosteroid was lower in the rush-HDM-IT group than in the control group. The HDM-induced production of both interleukin (IL)-5 and IL-13 from peripheral blood mononuclear cells was significantly lower in the rush-HDM-IT group than in the control group. CONCLUSION: Rush-HDM-IT can be performed relatively safely in Japanese asthmatics. Furthermore, rush-HDM-IT and the subsequent maintenance SCIT provided clinical improvement in asthma patients, and was accompanied by the suppression of HDM-specific Th2-mediated systemic immune responses.

7.
Allergol Int ; 67S: S3-S11, 2018 Sep.
Article in English | MEDLINE | ID: mdl-29754974

ABSTRACT

BACKGROUND: Severe asthma is a complex disease with heterogeneous features and involves type 2 airway inflammation, including eosinophil accumulation. Surrogate biomarkers, fraction of exhaled nitric oxide (FeNO) and blood eosinophil count (b-EOS), may predict eosinophilic airway inflammation. Here we investigated clinical characteristics of severe asthma phenotype using a combined analysis of FeNO and b-EOS. METHODS: This retrospective study examined clinical data of patients with severe asthma (N = 107; median age, 64 years) treated at Saitama Medical University Hospital from 2009 to 2016. Thresholds of FeNO and b-EOS for sputum eosinophil ratio ≥2% were determined using receiver operating characteristic curve (ROC) analysis. Clinical characteristics were analyzed after classifying patients into four subgroups according to these thresholds. RESULTS: Of 39 induced sputum samples examined, ROC area under the curve for predicting sputum eosinophilia was 82.0% (p = 0.001) for b-EOS and 77.0% (p = 0.006) for FeNO at optimal cut-off values of ≥300/µL and ≥25 ppb, respectively. The number of sensitized allergens was higher in the high FeNO/low b-EOS and high FeNO/high b-EOS subgroups (p < 0.05). The prevalence of chronic sinusitis was higher in the low FeNO/high b-EOS and high FeNO/high b-EOS subgroups (p = 0.04). The high FeNO/high b-EOS subgroup included the largest proportion (approximately 40%) of patients experiencing frequent severe exacerbations. Both low FeNO/low b-EOS and high FeNO/low b-EOS subgroups showed less severe exacerbations. CONCLUSIONS: Combined evaluation of FeNO and b-EOS can identify patients with frequent exacerbations and stratify the appropriate therapy for type 2 inflammation-predominant severe asthma.


Subject(s)
Asthma/immunology , Asthma/metabolism , Eosinophils/immunology , Nitric Oxide/metabolism , Adult , Aged , Aged, 80 and over , Asthma/epidemiology , Chronic Disease , Exhalation , Female , Humans , Leukocyte Count , Male , Middle Aged , Prevalence , ROC Curve , Retrospective Studies , Sinusitis/epidemiology , Sinusitis/immunology , Sinusitis/metabolism , Sputum/cytology , Young Adult
8.
Biocontrol Sci ; 15(4): 123-8, 2010 Dec.
Article in English | MEDLINE | ID: mdl-21212504

ABSTRACT

Sasa veitchii or "kumazasa" has been used for the preservation of food, or preventing bacterial activity. However, the antiviral activity of kumazasa is poorly understood. In the present study, the antiviral activity of kumazasa extract (KE) was assessed by the plaque reduction assay for the pseudorabies virus (PRV). KE reduced 99% of the plaque formation of PRV at concentrations of 1.2%, showing that KE inhibited PRV adsorption to cells and IE180 expression. The polysaccharide fraction of KE showed a concentration dependent inhibition of PRV plaque formation. We conclude that KE possesses potent anti PRV activity, and the candidate responsible for the antiviral property was the polysaccharide fraction.


Subject(s)
Herpesvirus 1, Suid/drug effects , Plant Extracts/pharmacology , Sasa , Animals , Chlorocebus aethiops , Polysaccharides/pharmacology , Vero Cells
SELECTION OF CITATIONS
SEARCH DETAIL
...